Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Development of Small Molecules to Reverse Presbyopia
Author Affiliations & Notes
  • Ram H Nagaraj
    Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado, United States
  • Footnotes
    Commercial Relationships   Ram Nagaraj LentoBio, Code C (Consultant/Contractor), University of Colorado, Code P (Patent)
  • Footnotes
    Support  NIH
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5590. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ram H Nagaraj; Development of Small Molecules to Reverse Presbyopia. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5590.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : We are developing small molecules to reduce lens stiffness and reverse presbyopia. These molecules, called "aggrelytes," have a unique dual function - they can acetylate lysine residues and reduce disulfide bonds in lens proteins. Previous studies have shown that aggrelyte-2 can increase water solubility in lens proteins and reduce stiffness in mice and human lenses. More recently, we conducted a study using a derivative of aggrelyte-2, called aggrelyte-2A, which, when applied topically to the eyes of mice, successfully reduced stiffness in the lens. More work needs to be done in order to develop aggrelytes into drugs that can potentially reverse presbyopia in humans.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×